REG - AstraZeneca PLC - AstraZeneca Completes Aspen Agreement <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

01/09/2016 07:06

RNS Number : 6199I
AstraZeneca PLC
01 September 2016
01 September 2016 07:00 BST
ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO
AstraZeneca today announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company's financial statements.
* With the exception of Ukraine and Zimbabwe, which are subject to separate closing
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 
CONTACTS
Media Enquiries
Neil Burrows
UK/Global
+44 203 749 5637
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677


Investor Relations


UK


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Nick Stone
Respiratory & Autoimmunity
+44 203 749 5716
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
Infection & Neuroscience
+44 203 749 5711
US


Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Mitchell Chan
Oncology
+1 240 477 3771
Toll-free

+1 866 381 7277
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
AGRAKDDNABKDQFN